Sánchez-Sáez F, Rodríguez-Bernal C L, Hurtado I, Riera-Arnau J, Garcia-Sempere A, Peiró Salvador, Sanfélix-Gimeno G
Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Avenida Cataluña, 21, 46020, Valencia, Spain.
Research Network on Chronic Diseases, Primary Healthcare and Health Promotion, [Red de Investigación en Cronicidad, Atención Primaria y Promoción de La Salud], RICCAPS, Valencia, Spain.
Sci Rep. 2024 Dec 30;14(1):31596. doi: 10.1038/s41598-024-79961-4.
Improvement of post-stroke outcomes relies on patient adherence and appropriate therapy maintenance by physicians. However, comprehensive evaluation of these factors is often overlooked. This study assesses secondary stroke prevention by differentiating patient adherence to antithrombotic treatments (ATT) from physician-initiated interruptions or switches. We analyzed a population-based retrospective cohort (n = 10,343) of post-stroke patients with atrial fibrillation using the VID database (2010-2017). Secondary prevention was evaluated based on patients' primary and secondary adherence to ATT at two years (percentage of days covered-PDC-and persistence/discontinuation) and physician prescription patterns (initiation, interruption, switching, restart). E-prescription and dispensing data were linked. Three ATT strategies were identified: oral anticoagulants (OAC), antiplatelets (APT), or combination therapy (OAC + APT), prescribed to 54%, 23%, and 17% of patients, respectively. Primary adherence was high for all ATTs (≈90%). OAC discontinuation was highest (16%), but frequently restarted (73.4%). APT treatment was interrupted the most (14%) and restarted the least (38.5%) by physicians, followed by OAC (interrupted in 11%, restarted in 65%). Overall, 17% of patients switched treatments, with OAC + APT being switched the most (76%), mainly to OAC (53.8%). Identifying areas for improvement in secondary stroke prevention requires considering both patient adherence and physician prescription patterns (initiation, interruptions, and restarts).
中风后预后的改善依赖于患者的依从性以及医生对适当治疗的持续维持。然而,对这些因素的全面评估常常被忽视。本研究通过区分患者对抗血栓治疗(ATT)的依从性与医生发起的治疗中断或换药情况来评估二级中风预防。我们使用VID数据库(2010 - 2017年)分析了一个基于人群的中风后房颤患者回顾性队列(n = 10343)。基于患者在两年时对ATT的一级和二级依从性(覆盖天数百分比 - PDC - 以及持续性/停药情况)和医生的处方模式(起始、中断、换药、重新开始)来评估二级预防。电子处方和配药数据相链接。确定了三种ATT策略:口服抗凝剂(OAC)、抗血小板药物(APT)或联合治疗(OAC + APT),分别开给了54%、23%和17%的患者。所有ATT的一级依从性都很高(约90%)。OAC停药率最高(16%),但频繁重新开始用药(73.4%)。医生对APT治疗的中断最为频繁(14%),重新开始用药最少(38.5%),其次是OAC(中断11%,重新开始65%)。总体而言,17%的患者更换了治疗方案,其中OAC + APT更换最多(76%),主要更换为OAC(53.8%)。确定二级中风预防中需要改进的领域需要同时考虑患者依从性和医生的处方模式(起始、中断和重新开始)。